GKOS
Glaukos Corporation
Is GKOS Halal?
Ophthalmic-device and pharmaceutical-therapy development — generally permissible activity whose known current asset-based ratios pass, with activity classification incomplete.
What You Should Know
Glaukos develops micro-invasive ophthalmic devices and pharmaceutical therapies. Its March 31, 2026 Form 10-Q reports assets of $893.326 million, finance-lease debt of $67.743 million, cash of $104.249 million, short-term investments of $172.436 million, receivables of $119.691 million and quarterly net sales of $150.571 million. Debt/assets is 7.58%, liquidity/assets is 30.97%, receivables plus cash/assets is 25.07% and disclosed interest income is 1.61% of revenue; known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed.
⚠️ Concerns
- •Known asset-based ratios pass, but no universal prohibited-revenue numerator is disclosed
- •Finance-lease liability and cash-investment profile require continuing review
- •Ophthalmic pharmaceutical and device pipeline risk
- •Disclosed interest income is 1.61% of quarterly revenue; no fixed purification percentage asserted
- •Clinical, regulatory and reimbursement exposure
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
67.743 / 893.326
276.685 / 893.326
223.94 / 893.326
2.431 / 150.571
- Financial
- Pass
- Overall
- Incomplete
Debt/assets is 7.58%, liquidity/assets is 30.97%, receivables-plus-cash/assets is 25.07% and disclosed interest income is 1.61%; activity remains qualitative.
- Financial
- Pass
- Overall
- Incomplete
Known debt, liquidity and receivables-plus-cash ratios are below the examined MSCI limits; this is not an index-membership claim and activity remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Debt/assets and identifiable liquidity/assets are below the examined Malaysia limits; this is a calculation against SAC ratios, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
Glaukos develops micro-invasive ophthalmic devices and pharmaceutical therapies for glaucoma and corneal disease. The core medical-device and therapeutic-development activity is generally permissible, but the filing does not provide a universal prohibited-revenue numerator for product or customer end uses.
Limitation: No universal prohibited-activity revenue numerator or scholar-specific purification percentage is disclosed; product and clinical-use allocation remains qualitative.
Purification
The filing discloses $2.431 million of interest income; ZakatInvest does not prescribe a fixed scholar-approved purification percentage.
Inputs, assumptions and primary sources
- Amounts are USD millions from Glaukos's March 31, 2026 Form 10-Q.
- Interest-bearing debt uses the $67.743 million finance-lease liability; no conventional notes or borrowings are reported and operating leases are excluded.
- Cash and cash equivalents are $104.249 million and short-term investments are $172.436 million; net accounts receivable are $119.691 million.
- First-quarter net sales are $150.571 million and disclosed interest income is $2.431 million (1.61% of revenue).
- Ophthalmic-device and pharmaceutical-therapy activity is retained as qualitative analysis; no universal prohibited-revenue numerator is disclosed.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →